

Global Glaucoma Treatment Market - Trends And Opportunities: 2015 Edition

<https://marketpublishers.com/r/G342BB0301DEN.html>

Date: July 2015

Pages: 80

Price: US\$ 1,200.00 (Single User License)

ID: G342BB0301DEN

Abstracts

Scope of the Report

The report titled “Global Glaucoma Treatment Market: Trends and Opportunities (2015 Edition)” analyzes the potential opportunities, challenges, demand drivers and significant trends representing the Glaucoma treatment market. The report elucidates facts on the glaucoma treatment market as supplemented by the latest available statistics. It also profiles and analyzes the leading four companies operating in this industry with latest data and a brief overview of their business and financial performance along with a brief discussion of their future business strategies. The report gives valuable insight into technology used in glaucoma treatment market, its demand in various geographies. In the report, we also try to study the growth pattern in the prescriptions and revenue earned by the glaucoma treatment companies and the latest trends concerning glaucoma treatment market. Most importantly, we have analyzed the current market size and project future market size of the overall glaucoma treatment market for the years to come.

Company Coverage

Biolite Israeli

Pfizer Inc.

Merck & Co. Inc.

Alcon (A division of Novartis)

Products Covered

Prostaglandin

Combination Market

Carbonic Anhydrase Inhibitor

Beta Blocker

Alpha Agonist & Cholinergic

Surgical Devices

Executive Summary

The global Glaucoma market has been growing rapidly since the past several years mainly due to innovation such as introduction of IOPtiMa, OTP-TX, anti-VEGF therapy, photodynamic therapy (PDT) laser photocoagulation, Rhopressa, latanoprost and Vesneo. Among the several varieties of drugs and surgeries available in the market, the demand for drugs such as Prostaglandins which includes Trabatan, Lumbigan are the highest due to its high efficiency in treating glaucoma. Vesneo has shown a superior intraocular pressure reduction effect on beta-blocker timolol, the most widely used comparator in registration trials for glaucoma, in two phase 3 studies.

Globally, the major factors contributing to the growth of Glaucoma treatment market is the higher number of glaucoma patients from the U.S, Europe and Japan. Novel therapies for glaucoma are constantly being investigated by research and development teams of various pharmaceutical companies, at different stages. It can be predicted that novel therapies that work in conjunction with current drugs, such as Prostaglandins, will likely be increasingly common in the near future.

Growth of the Glaucoma treatment market could also be attributed to North America where the number of patients suffering from glaucoma is the highest among the rest of the U.S and also from emerging markets such as France and Singapore driven by rapid increase of old age population. Moreover, the Asian market is expected to become a huge potential market for glaucoma surgery devices in the foreseeable future, as it is expected to grow at comparatively the fastest among all other regions. It is estimated

that by 2020, 11 million individuals will have vision loss due to glaucoma.

Glaucoma market is seen as a diversifying risk to other lines of ophthalmic treatment business and is attracting more and more revenue. Glaucoma treatment companies are launching new technologies and adopting new strategies in the industry and making significant investments.

Contents

1. EXECUTIVE SUMMARY

2. GLAUCOMA: A CAUSE FOR VISION LOSS

2.1 Overview

2.2 Types of Glaucoma

2.3 Prevention and Treatment of Glaucoma

3. GLOBAL GLAUCOMA TREATMENT MARKET: SIZE AND GROWTH

4. GLAUCOMA MARKET: REGIONAL/COUNTRY ANALYSIS

4.1 U.S Glaucoma Treatment Market Analysis: Size and Growth

4.2 U.S Glaucoma Treatment Market Analysis: By Drugs

4.2.1 U.S Prostaglandin Market: Size and Segmentation

4.2.2 U.S Combination Market: Size and Segmentation

4.2.3 U.S Carbonic Anhydrase Inhibitors Market: Size and Segmentation

4.2.4 U.S Beta Blocker Market: Size and Segmentation

4.2.5 U.S Alpha Agonist and Cholinergic Market: Size and Segmentation

4.3 U.S Vesneo (Glaucoma) Market: An Analysis

4.4 U.S Glaucoma Surgical Devices Market: An Analysis

4.5 Europe7 Vesneo (Glaucoma) Market: An Analysis

4.6 Japan Glaucoma Treatment Market: An Analysis

4.7 Japan Glaucoma Treatment Market Analysis: By Drugs

4.7.1 Tapros Market Size: An Analysis

4.7.2 Cosopt Market Size: An Analysis

4.8 Japan Vesneo (Glaucoma) Market: An Analysis

5. GLOBAL GLAUCOMA MARKET SHARE: AN ANALYSIS

5.1 U.S Glaucoma Treatment Market Share: An Analysis

5.2 Japan Glaucoma Treatment Market Share: An Analysis

6. MARKET DYNAMICSGLOBAL GLAUCOMA MARKET

6.1 Growth DriversGlobal Glaucoma Market

6.1.1 Innovation

- 6.1.2 Rising Old Age Population
- 6.1.3 Rising Global Healthcare expenditure
- 6.1.4 Alternative Drug Delivery Methods to Treat Glaucoma
- 6.2 Challenges:Global Glaucoma Market
 - 6.2.1 Vision Loss and Bleeding from Eye
 - 6.2.2 Infection
 - 6.2.3 Side Effects of Glaucoma Drugs
- 6.3 Market Trends:Global Glaucoma Market
 - 6.3.1 Anti-VEGF Market Opportunity will continue to Expand
 - 6.3.2 New Glaucoma Drugs to Accelerate Glaucoma Treatment Market
 - 6.3.3 Glaucoma Treatment Ideal for Treating TB
 - 6.3.4 Glaucoma being the second largest reason for blindness
 - 6.3.5 New Treatments to Reduce Intra Ocular Pressure to Treat Glaucoma
 - 6.3.6 Prostaglandin Drugs Most Popular For Glaucoma Treatment

7. COMPETITIVE LANDSCAPE:GLOBAL GLAUCOMA MARKET

World's leading companies and their comparative analysis

8. COMPANY PROFILES:GLOBAL GLAUCOMA MARKET

- 8.1 Biolight Israeli
 - 8.1.1 Business Overview
 - 8.1.2 Financial Overview
 - 8.1.3 Business Strategies
- 8.2 Pfizer Inc.
 - 8.2.1 Business Overview
 - 8.3.2 Financial Overview
 - 8.3.3 Business Strategies
- 8.3 Merck & Co. Inc.
 - 8.3.1 Business Overview
 - 8.3.2 Financial Overview
 - 8.3.4 Business Strategies
- 8.4 Alcon (A division of Novartis)
 - 8.4.1 Business Overview
 - 8.4.2 Financial Overview
 - 8.4.3 Business Strategies

Figures & Tables

LIST OF FIGURES AND TABLES

- Figure 1: Diagrammatic Representation of a Normal Eye
- Figure 2: Diagrammatic Representation of Developing Glaucoma
- Figure 3: Diagrammatic Representation of Open Angle Glaucoma
- Figure 4: Diagrammatic Representation of Angle Closure Glaucoma
- Figure 5: Diagrammatic Representation of Argon Laser Trabeculoplasty
- Figure 6: Diagrammatic Representation of Selective Laser Trabeculoplasty
- Figure 7: Diagrammatic Representation of Laser Iridotomy
- Figure 8: Diagrammatic Representation of Trabeculectomy
- Figure 9: Diagrammatic Representation of Drainage System Surgery
- Figure 10: Global Glaucoma Treatment Market-(US\$ Million)-2012-2014
- Figure 11: Total Number of Prescriptions issued Worldwide for Glaucoma Treatment-(Million)-2012-2014E
- Figure 12: Global Glaucoma Treatment Market-(US\$ Million)-2015-2019
- Figure 13: Total Number of Prescriptions forecasted to be issued Worldwide for Glaucoma Treatment-(Million)-2015-2019
- Figure 14: U.S Glaucoma Treatment Market-(US\$ Billion)-2012-2014E
- Figure 15: Total Number of Prescriptions issued in U.S for Glaucoma Treatment-(Million)-2012-2014E
- Figure 16: U.S Glaucoma Treatment Market Forecast-(US\$ Billion)-2015-2019
- Figure 17: Total Number of Prescriptions issued in U.S for Glaucoma Treatment-(Million)-2015-2019
- Figure 18: U.S Prostaglandin Market-(2012-2013)
- Figure 19: U.S Trabatan Market-(2012-2013)
- Figure 20: U.S Lumbigan Market-(2012-2013)
- Figure 21: U.S Combination Market-(2012-2013)
- Figure 22: U.S Cosopt Market-(2012-2013)
- Figure 23: U.S Combigan Market-(2012-2013)
- Figure 24: U.S Carbonic Anhydrase Inhibitors Market-(2012-2013)
- Figure 25: U.S Carbonic Anhydrase Inhibitor Branded Market-(2012-2013)
- Figure 26: U.S Beta Blocker Market-(2012-2013)
- Figure 27: U.S Beta Blocker (Branded) Market-(2012-2013)
- Figure 28: U.S Alpha Agonist and Cholinergic Market-(2012-2013)
- Figure 29: U.S Alphagan Market-(2012-2013)
- Figure 30: Expected Prevalence of Vesneo(Glaucoma) in U.S-(Millions)-2015-2020
- Figure 31: Expected Prescriptions of Vesneo(Glaucoma) in U.S-(Millions)-2015-2020

- Figure 32: U.S Glaucoma Surgical Devices Market-(US\$ Billion)-2012-2014E
- Figure 33: Expected Prevalence of Vesneo(Glaucoma) in Europe7-(Millions)-2015-2020
- Figure 34: Expected Prescription of Vesneo(Glaucoma) in Europe7-(Millions)-2015-2020
- Figure 35: Japan Glaucoma Treatment Market-(US\$ Million)-20112-2014E
- Figure 36: Japan Glaucoma Drug Treatment Market-(US\$ Million)-2010-2013
- Figure 37: Japan Tapros Market-(US\$ Million)-2010-2013
- Figure 38: Japan Cosopt Market-(US\$ Million)-2010-2013
- Figure 39: Expected Prevalence of Vesneo in Japan-(Million)-2015-2020
- Figure 40: Expected Prescriptions of Vesneo in Japan-(Million)-2015-2020
- Figure 41: Global Glaucoma Market Share-(By Region)-2013
- Figure 42: Break-Up of U.S. Glaucoma Treatment Market-(By Treatment Types)-2013
- Figure 43: Break-Up of Glaucoma Treatment Market-(By Drug Types)-2013
- Figure 44: Break-Up of Prostaglandin Market for Glaucoma Treatment-(2013)
- Figure 45: Break-Up of Combination Market for Glaucoma Treatment-(2013)
- Figure 46: Break-Up of Carbonic Anhydrase Market for Glaucoma Treatment-(2013)
- Figure 47: Break-Up of Beta Blocker Market for Glaucoma Treatment-(2013)
- Figure 48: Break-Up of Alpha Agonist and Cholinergic Market for Glaucoma Treatment-(2013)
- Figure 49: Japan Glaucoma Market Share-(By Treatment Types)-2013
- Figure 50: Japan Glaucoma Market Share-(By Drug Types)-2013
- Figure 51: Fluid Percolation through Fluid Intact Thinned Sclera by IOptima
- Figure 52: Rising Global Old Age Population-(Billion)-1990-2035E
- Figure 53: Global Healthcare Expenditure-(US\$ Trillion)-2009-2013
- Figure 54: Break-Up of Eye Drop Types for Glaucoma Treatment-(By Popularity)
- Figure 55: Market share of leading companies in Glaucoma Treatment-(Surgical Devices)-2013
- Figure 56: Biolight Israeli Consolidated Revenue-(US\$ Million)-2011-2014
- Figure 57: Biolight Israeli Revenue Break-up-(Sector)-2014
- Figure 58: Biolight Israeli Revenue Break-up-(Sector)-2013
- Figure 59: Expenses in Research and Development- (US\$ Million)-2011-2014
- Figure 60: Pfizer Revenue from Xalatan and Xalacom-(US\$ Million)-2012-2014
- Figure 61: Pfizer Consolidated Net Income-(US\$ Million)-2012-2014
- Figure 62: Merck & Co. Revenue of Cosopt/Trusopt-(US\$ Million)-2012-2014
- Figure 63: Consolidated Net Income-(US\$ Billion)-2012-2014
- Figure 64: Alcon Consolidated Revenue-(US\$ Million)-2011-2014
- Figure 65: Alcon Revenue Break-Up by Franchises-(Percentage)-2013
- Figure 66: Alcon Revenue Break-Up of Ophthalmic Pharmaceuticals-(Percentage)-2013
- Figure 67: Alcon Revenue Break-Up by Franchises-(Percentage)-2014

Table 1: List of Tests for Glaucoma Detection

Table 2: List of Drugs Used in U.S Glaucoma Treatment Market-(2013)

Table 3: List of Alternative Drug Delivery Methods to Treat Glaucoma

I would like to order

Product name: Global Glaucoma Treatment Market - Trends And Opportunities: 2015 Edition

Product link: <https://marketpublishers.com/r/G342BB0301DEN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G342BB0301DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970